Omar Faruk Bhuiyan

Omar Faruk Bhuiyan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
PDF file
ARAura Rahman
Aura Rahman
OBOmar Faruk Bhuiyan
Omar Faruk Bhuiyan
ASAbdus Sadique
Abdus Sadique
TATamanna Afroze
Tamanna Afroze
MSMrinmoy Sarker
Mrinmoy Sarker
MHMUHAMMAD MAQSUD HOSSAIN
MUHAMMAD MAQSUD HOSSAIN
Morganella morganii, a gram negative, facultative anaerobic bacterium belonging to the Proteeae tribe of the Morganellaceae family, is an unusual opportunistic pathogen mainly responsible for nosocomial and urinary tract infections. While cattle have long been established as a source of a few zoonotic pathogens, no such data has been recorded for M. morganii despite its ubiquitous presence in nature and a number of animal hosts. In this study, draft genomes were produced of three M. morganii isolates from Bangladeshi cattle. The three isolates, named B2, B3 and B5 possessed an average genome size of 3.9 Mp, a GC% of ∼51% and a pan and core genome of 4637 and 3812 genes, respectively. All strains were bearers of qnrD1 carrying plasmid Col3M and possessed roughly similar virulence profiles and prophage regions. The strains also carried genes that were unique when compared against other publicly available M. morganii genomes. Many of these genes belonged to metabolic pathways associated with adaptation to environmental stresses, and were predicted in silico to be borne in genomic islands. The findings of this study expand on the current understanding of M. morganii’s genomic nature and its adaptation in cattle.

2 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ASAshley Styczynski
Ashley Styczynski
CHCaitlin Hemlock
Caitlin Hemlock
KHKazi Injamamul Hoque
Kazi Injamamul Hoque
RVRenu Verma
Renu Verma
CLChris LeBoa
Chris LeBoa
JAJason R. Andrews
Jason R. Andrews
Background: In healthcare settings in low- and middle-income countries, which frequently rely upon natural ventilation, the risk of aerosol transmission of SARS-CoV-2 remains poorly understood. We aimed to evaluate the risk of exposure to SARS-CoV-2 in naturally-ventilated hospital settings by measuring parameters of ventilation and comparing these findings with results of bioaerosol sampling. Methods: We measured outdoor and room CO 2 to estimate absolute ventilation (liters per second [L/s]) from 9 hospitals in Bangladesh during October 2020 - February 2021. We estimated infectious risk across different spaces using a modified Wells-Riley equation. We collected air samples from these same spaces at 12.5 L/min over 30 minutes and performed RT-qPCR to detect SARS-CoV-2 N-gene. We used multivariable linear regression and calculated elasticity to identify characteristics associated with ventilation. Results: Based on ventilation of 86 patient care areas and COVID-19 case numbers, we found that over a 40-hour exposure period, outpatient departments posed the highest median risk for infection (5.4%), followed by COVID intensive care units (1.8%). We detected SARS-CoV-2 RNA in 18.6% (16/86) of air samples. Ceiling height and total open area of doors and windows were found to have the greatest impact on ventilation. Conclusion: Our findings provide evidence that naturally-ventilated healthcare settings may pose a high risk for exposure to SARS-CoV-2, particularly among non-COVID designated spaces, but improving parameters of ventilation can mitigate this risk.

30 December 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
KAKazi Faizul Azim
Kazi Faizul Azim
TLTahera Lasker
Tahera Lasker
RARahima Akter
Rahima Akter
MHMantasha Mahmud Hia
Mantasha Mahmud Hia
OBOmar Faruk Bhuiyan
Omar Faruk Bhuiyan
NHNazmul Hossain
Nazmul Hossain
: Arenaviral infections often resulting in lethal Hemorrhagic Fevers (HF) affect primarily African and South American regions. To date, there is no FDA-approved licensed vaccine against arenaviruses and treatments have been limited to supportive therapies. Hence, the study was employed to design a highly immunogenic heterosubtypic vaccine candidate against Arenaviridae family. The whole proteomes of Lassa virus (LASV), Lymphocytic Chorio Meningitis Virus (LCMV), Lujo virus and Guanarito virus were retrieved from NCBI database and assessed to determine the most antigenic viral proteins. Only the conserved sequences were used for T cell and B cell epitope prediction to ensure protective response against a wide range of viral strains. For each virus, nucleoproteins were identified as most antigenic which generated a plethora of antigenic epitopes. The proposed epitopes were highly conserved (up to 100%) and showed high cumulative population coverage. Moreover, results revealed that among the top epitopes, T cell epitope GWPYIGSRS were conserved in Argentine mammarenavirus (Junin virus) and Brazilian mammarenavirus (Sabia virus), while B cell epitope NLLYKICLSG were conserved in Bolivian mammarenavirus (Machupo virus) and Brazilian mammarenavirus (Sabia virus), indicating the possibility of final vaccine constructs to confer broad range immunity in the host. A total 3 constructs were designed by the combination of top epitopes from each protein along with suitable adjuvant and linkers. Different physicochemical properties revealed the superiority of construct V1 in terms of safety and efficacy. Docking analysis of the refined vaccine structure with different MHC molecules and human immune receptors were also biologically significant. The vaccine receptor complex (V1-TLR3) showed minimal deformability at molecular level. Moreover, construct V1 was compatible for insertion into pET28a(+) vector and heterologous cloning inE. colisrain K12. However, the results were based on different sequence analysis and various immune databases. Further wet lab based studies using model animals are highly recommended for the experimental validation of the designed vaccine candidates.

11 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OBOmar Faruk Bhuiyan
Omar Faruk Bhuiyan
MHMuhammad Taki Hasan
Muhammad Taki Hasan
ATAfrida Tabassum
Afrida Tabassum
SASamiul Alam
Samiul Alam
SISamiha Islam
Samiha Islam
SNSyed Mohammed Nuruddin
Syed Mohammed Nuruddin
Respiratory tract cancers (RTCs), including lung, laryngeal, nasopharyngeal, and tracheal cancers, are among the most common cancer types. These cancers show difficulties in the case of early diagnosis and treatment monitoring. The microbiome, the community of microbes living in a single area of the body, is associated with cancer and offers potential for developing non-invasive diagnostic tools and probiotic therapies. Microbiome dysbiosis affects both the tumor and the immune microenvironment. The major pathways of RTCs, including EGFR, ALK, KRAS, STAT3, WNT, etc., are affected by the dysbiosis that occurs during cancer progression. Several microbial species have also been associated with treatment outcomes of immune checkpoint inhibitors (ICIs), chemotherapy, and anti-PD-1 therapy. Microbes such as Alistipes indistinctus, Alistipes shahii, Barnesiella viscericola, Streptococcus salivarius, Parabacteroides, and Faecalibacterium, along with genera like Bifidobacterium, Collinsella, Veillonella, and families/orders like Actinomycetales, Odoribacteraceae, and Selenomonadales, have shown positive associations with overall survival, progression-free survival, and improved treatment responses. Conventional biomarkers for RTCs have greatly improved diagnosis and monitoring. Still, they suffer from limitations such as low sensitivity in early-stage, intrusive sample procedures, and a lack of specificity. In contrast, gut, airway, and oral microbiota have emerged as promising non-invasive biomarkers with established associations to cancer progression, metabolic pathways, immune responses, and treatment monitoring. Moreover, non-invasive sampling methods like stool, sputum, and oral swabs offer improved patient comfort and early detection opportunities. In this mini review, we explore global research on human microbiomes as potential diagnostic or therapeutic biomarkers and their associations with RTCs.